TNFα inhibits the development of osteoclasts through osteoblast-derived GM-CSF

Bone

Volumn 49, Issue 5, 2011, Pages 1090-1100

  Atanga, Elvis ^a   Dolder, Silvia ^a   Dauwalder, Tina ^b   Wetterwald, Antoinette ^a   Hofstetter, Willy ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b CSL Behring Biotherapies for Life   (Switzerland)

Author keywords

Differentiation; GM CSF; Inflammation; Osteoclastogenesis; TNF

Indexed keywords

CALCITRIOL; COLONY STIMULATING FACTOR 1; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; COCULTURE; CONTROLLED STUDY; DENDRITIC CELL; FRA 1 GENE; GENE; GENE EXPRESSION; IN VITRO STUDY; MONOCYTE; MOUSE; NFATC 1 GENE; NONHUMAN; ONCOGENE C FOS; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; STEM CELL;

ANIMALS; CALCITRIOL; CELLS, CULTURED; DEXAMETHASONE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOCLASTS; POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054833809     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.08.003     Document Type: Article

References (64)

1. Boyce B.F., Li P., Yao Z., Zhang Q., Badell I.R., Schwarz E.M., et al. TNF-alpha and pathologic bone resorption. Keio J Med 2005, 54:127-131.
2. Lee S.H., Kim T.S., Choi Y., Lorenzo J. Osteoimmunology: cytokines and the skeletal system. BMB Rep 2008, 41:495-510.
3. Wakkach A., Mansour A., Dacquin R., Coste E., Jurdic P., Carle G.F., et al. Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood 2008, 112:5074-5083.
4. Ochi S., Shinohara M., Sato K., Gober H.J., Koga T., Kodama T., et al. Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc Natl Acad Sci U S A 2007, 104:11394-11399.
5. Schett G. Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009, 11:210.
6. Schett G., Teitelbaum S.L. Osteoclasts and arthritis. J Bone Miner Res 2009, 24:1142-1146.
7. Li X., Yuan F.L., Lu W.G., Zhao Y.Q., Li C.W., Li J.P., et al. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun 2010, 397:131-135.
8. Yamashita A., Nishikawa S., Rancourt D.E. Microenvironment modulates osteogenic cell lineage commitment in differentiated embryonic stem cells. PLoS One 2010, 5:e9663.
9. Yuan F.L., Li X., Lu W.G., Xu R.S., Zhao Y.Q., Li C.W., et al. Regulatory T cells as a potent target for controlling bone loss. Biochem Biophys Res Commun 2010, 402:173-176.
10. Feldmann M., Maini R.N., Bondeson J., Taylor P., Foxwell B.M., Brennan F.M. Cytokine blockade in rheumatoid arthritis. Adv Exp Med Biol 2001, 490:119-127.
11. Moreland L.W. Cytokines as targets for anti-inflammatory agents. Ann N Y Acad Sci 2009, 1182:88-96.
12. Plushner S.L. Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2008, 42:1660-1668.
13. Woodrick R., Ruderman E.M. Anti-interleukin-6 therapy in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2010, 68:211-217.
14. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001, 19:163-196.
15. Maini R.N. Anti-TNF therapy from the bench to the clinic: a paradigm of translational research. Clin Med 2010, 10:161-162.
16. McCluggage L.K., Scholtz J.M. Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2010, 44:135-144.
17. Shinohara M., Takayanagi H. Novel osteoclast signaling mechanisms. Curr Osteoporos Rep 2007, 5:67-72.
18. Aeschlimann D., Evans B.A. The vital osteoclast: how is it regulated?. Cell Death Differ 2004, 11(Suppl. 1):S5-S7.
19. Teitelbaum S.L. Osteoclasts: what do they do and how do they do it?. Am J Pathol 2007, 170:427-435.
20. Boyce B.F., Yamashita T., Yao Z., Zhang Q., Li F., Xing L. Roles for NF-kappaB and c-Fos in osteoclasts. J Bone Miner Metab 2005, 23(Suppl):11-15.
21. Xing L., Schwarz E.M., Boyce B.F. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 2005, 208:19-29.
22. Wada T., Nakashima T., Hiroshi N., Penninger J.M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006, 12:17-25.
23. Chakravarti A., Raquil M.A., Tessier P., Poubelle P.E. Surface RANKL of Toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption. Blood 2009, 114:1633-1644.
24. Goldring S.R. Bone loss in chronic inflammatory conditions. J Musculoskelet Neuronal Interact 2003, 3:287-289. [discussion 292-4].
25. Goldring S.R. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 2003, 42(Suppl. 2):ii11-ii16.
26. Choi Y., Woo K.M., Ko S.H., Lee Y.J., Park S.J., Kim H.M., et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol 2001, 31:2179-2188.
27. Manabe N., Kawaguchi H., Chikuda H., Miyaura C., Inada M., Nagai R., et al. Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 2001, 167:2625-2631.
28. Kawai T., Matsuyama T., Hosokawa Y., Makihira S., Seki M., Karimbux N.Y., et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006, 169:987-998.
29. Soderstrom K., Stein E., Colmenero P., Purath U., Muller-Ladner U., de Matos C.T., et al. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci U S A 2010, 107:13028-13033.
30. Quinn J.M., Gillespie M.T. Modulation of osteoclast formation. Biochem Biophys Res Commun 2005, 328:739-745.
31. Inoue M., Ross F.P., Erdmann J.M., Abu-Amer Y., Wei S., Teitelbaum S.L. Tumor necrosis factor alpha regulates alpha(v)beta5 integrin expression by osteoclast precursors in vitro and in vivo. Endocrinology 2000, 141:284-290.
32. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191:275-286.
33. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106:1481-1488.
34. Zhang Q., Badell I.R., Schwarz E.M., Boulukos K.E., Yao Z., Boyce B.F., et al. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum 2005, 52:2708-2718.
35. Benayahu D., Gurevitch O., Zipori D., Wientroub S. Bone formation by marrow osteogenic cells (MBA-15) is not accompanied by osteoclastogenesis and generation of hematopoietic supportive microenvironment. J Bone Miner Res 1994, 9:1107-1114.
36. Brandstrom H., Jonsson K.B., Vidal O., Ljunghall S., Ohlsson C., Ljunggren O. Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 1998, 248:454-457.
37. Kubota A., Hasegawa K., Suguro T., Koshihara Y. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. J Rheumatol 2004, 31:426-435.
38. Balga R., Wetterwald A., Portenier J., Dolder S., Mueller C., Hofstetter W. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro. Bone 2006, 39:325-335.
39. Miyamoto T., Ohneda O., Arai F., Iwamoto K., Okada S., Takagi K., et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001, 98:2544-2554.
40. Bluml S., Binder N.B., Niederreiter B., Polzer K., Hayer S., Tauber S., et al. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum 2010, 62:1608-1619.
41. Polzer K., Joosten L., Gasser J., Distler J.H., Ruiz G., Baum W., et al. Interleukin-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis 2010, 69:284-290.
42. Herman S., Muller R.B., Kronke G., Zwerina J., Redlich K., Hueber A.J., et al. Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum 2008, 58:3041-3050.
43. Zwerina J., Redlich K., Polzer K., Joosten L., Kronke G., Distler J., et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A 2007, 104:11742-11747.
44. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002, 110:1419-1427.
45. Redlich K., Hayer S., Maier A., Dunstan C.R., Tohidast-Akrad M., Lang S., et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002, 46:785-792.
46. Lacativa P.G., Farias M.L. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol 2010, 54:123-132.
47. Koeffler H.P., Gasson J., Ranyard J., Souza L., Shepard M., Munker R. Recombinant human TNF alpha stimulates production of granulocyte colony-stimulating factor. Blood 1987, 70:55-59.
48. Burgess A.W., Metcalf D. The nature and action of granulocyte-macrophage colony stimulating factors. Blood 1980, 56:947-958.
49. Munker R., DiPersio J., Koeffler H.P. Tumor necrosis factor: receptors on hematopoietic cells. Blood 1987, 70:1730-1734.
50. Munker R., Gasson J., Ogawa M., Koeffler H.P. Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature 1986, 323:79-82.
51. Haworth C., Brennan F.M., Chantry D., Turner M., Maini R.N., Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 1991, 21:2575-2579.
52. Alsalameh S., Firestein G.S., Oez S., Kurrle R., Kalden J.R., Burmester G.R. Regulation of granulocyte macrophage colony stimulating factor production by human articular chondrocytes. Induction by both tumor necrosis factor-alpha and interleukin 1, downregulation by transforming growth factor beta and upregulation by fibroblast growth factor. J Rheumatol 1994, 21:993-1002.
53. Taichman R.S., Emerson S.G. Human osteosarcoma cell lines MG-63 and SaOS-2 produce G-CSF and GM-CSF: identification and partial characterization of cell-associated isoforms. Exp Hematol 1996, 24:509-517.
54. Taichman R.S., Emerson S.G. Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J Exp Med 1994, 179:1677-1682.
55. Schreck R., Baeuerle P.A. NF-kappa B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene. Mol Cell Biol 1990, 10:1281-1286.
56. Brettingham-Moore K.H., Rao S., Juelich T., Shannon M.F., Holloway A.F. GM-CSF promoter chromatin remodelling and gene transcription display distinct signal and transcription factor requirements. Nucleic Acids Res 2005, 33:225-234.
57. Towers T.L., Freedman L.P. Granulocyte-macrophage colony-stimulating factor gene transcription is directly repressed by the vitamin D3 receptor. Implications for allosteric influences on nuclear receptor structure and function by a DNA element. J Biol Chem 1998, 273:10338-10348.
58. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000, 97:1566-1571.
59. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266:443-448.
60. Fleischmann A., Hafezi F., Elliott C., Reme C.E., Ruther U., Wagner E.F. Fra-1 replaces c-Fos-dependent functions in mice. Genes Dev 2000, 14:2695-2700.
61. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
62. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005, 202:1261-1269.
63. Hofstetter W., Siegrist M., Simonin A., Bonny O., Fuster D.G. Sodium/hydrogen exchanger NHA2 in osteoclasts: subcellular localization and role in vitro and in vivo. Bone 2010, 47:331-340.
64. Ishii T., Shimazu Y., Nishiyama I., Kikuta J., Ishii M. The role of sphingosine 1-phosphate in migration of osteoclast precursors; an application of intravital two-photon microscopy. Mol Cells 2011, 31:399-403.